Dr. Bocheng Wu is a chemical biologist with over 8 years of experience in small molecule drug discovery. His multidisciplinary training spans medicinal chemistry, chemical biology, and translational research. He gained his bachelor degree of Chemistry from Marquette University and graduated as a Ph.D. of Chemistry from Adegboyega Oyelere lab in Georgia Tech. Later, he was trained by Angela Koehler from Massachusetts Institute of Technology.

​

At MIT, Dr. Wu’s postdoctoral research focuses on developing small molecules against traditionally “undruggable” transcription factors involved in immuno-oncology and cardiovascular disease. His major scientific contributions in immunology include TOX inhibitors that reverse T cell exhaustion and induce selective cytotoxicity in TOX-dependent T-ALL cells, and NR4A1 ligands targeting both ligand-binding and DNA-binding domains to create novel probes and degraders for T cell dysfunction. In addition to immunology, Dr. Wu has contributed to several other diseases. With collaboration to University of Texas Medical Branch, Dr. Wu and Dr. Chen collaborated to an anti-thrombosis project, where he found a vWF-GPIbα disruptors that block thrombosis initiation without bleeding risk—offering a promising anti-heart attack strategy.​ As a chemist, Dr. Wu also contributed significantly in proximity-induced degraders of PAX3-FOXO1, a fusion oncogene driving pediatric rhabdomyosarcoma.

​

In Georgia Tech, Dr. Wu has contributed with drug discovery in tissue fibrosis, including pulmonary fibrosis and liver fibrosis. The novel drugs are under further investigation in animal in vivo studies. In addition, he made several tumor-selective epigenetic regulators to re-model the tumor microenvironment and activate the immune response in solid tumors and the top candidates revealed promising anti-cancer activities.

​

Dr. Wu's work leverages high-throughput screening, small molecule microarrays, and medicinal chemistry to innovate chemical probes and first-in-class therapeutics. He has received the PhRMA Foundation Postdoctoral Fellowship in Drug Discovery and the Koch Institute Frontier Award, and he has authored over 15 peer-reviewed publications and several patents.